Upcoming fiscal second-quarter earnings release in September 2026 serves as a key near-term catalyst for assessing revenue growth and AI feature adoption. GitLab maintains a leadership position in the DevOps platform market with its single-application approach, supported by ongoing AI enhancements and strategic partnerships such as the expanded collaboration with Google Cloud.

Selected price target: $50 per share, implying roughly 28% upside from the latest close near $39. Strongest bullish factors: a 12-month analyst consensus target near $50.66, Nike’s global brand scale, an improving wholesale channel, and a dividend yield above 4%.

SMCI shares rose from a July 17 close of $24.18 to $38.28 on August 17, 2026, a gain of about 58.3% over the trailing 30-day comparison. The move was powered by fiscal fourth-quarter results: adjusted EPS of $1.70, non-GAAP gross margin of 17.6%, and more than $60 billion in new orders.

Selected price target: $80 per share, roughly 40% above SLV's early-August trading range near $56–58. Strongest bullish factors: a multi-year silver supply deficit, industrial demand from solar, electronics, and data centers, and physical supply constraints.

Everpure shares closed at $116.99 on Aug. 17, 2026, up about 68.6% from the $69.38 close on July 17, 2026, the nearest prior trading session to 30 days earlier. The August advance was driven by a second top-five hyperscaler design win and supply agreement, followed by a wave of analyst upgrades and price-target increases.

Atlassian shares climbed about 69.7% over the trailing 30 days, from a closing price of $93.29 on July 17, 2026, to $158.34 at the Aug. 17, 2026 close. The advance accelerated after fiscal Q4 2026 results reported Aug. 6 beat expectations: adjusted EPS of $1.87 versus a $1.50 consensus, with revenue of roughly $1.77 billion against approximately $1.66 billion expected.

Selected price target: $200, roughly 89% above the latest close of $106.00. Strongest bullish factors: triple-digit revenue growth, a massive contracted backlog, expanding AI data-center capacity, and deep ties to Nvidia and major AI customers.

TER shares advanced roughly 37% over the 30 days through mid-August 2026, rebounding from a sharp July pullback. The recovery followed Teradyne's Q2 2026 results: revenue of $1.33 billion, up about 104% year over year, and non-GAAP EPS of $2.47, both above consensus.

Nebius Group shares climbed about 51.3% in the 30-day window ended August 17, 2026, rising from $177.71 to $268.85. The move was driven primarily by second-quarter results released August 12, including revenue of $582.3 million, up 454% year over year.

AIRS is down -11.37% at $3.04 during Monday’s regular session (3:16 PM ET), versus Friday’s close of $3.43. The selling extends post-Q2-earnings volatility: revenue fell to $42.9M from $44.01M, net loss widened, and FY26 revenue guidance was reaffirmed only at the lower end of $151M-$157M.

LFTO is down -9.07% to $19.65 during Monday regular trading, versus Friday's $21.61 close. The decline extends the stock's post-earnings slide despite Q2 revenue of $219.5M beating consensus and Q3/FY26 guidance topping estimates.

ODD fell -9.84% during Monday’s regular session to $11.82, versus Friday’s $13.11 close. No company-specific headline drove the move; selling continues the post-Q1 slide tied to the ad-algorithm dislocation that doubled customer acquisition costs and cut revenue -26%.

PICS is down -9.81% to $10.30 in regular Monday trading, versus Friday's close of $11.42. The decline occurred during market hours, not premarket or after-hours; shares were already off about -7.6% near midday and weakened further into the afternoon.

EMAT is trading down -11.63% at $2.68 on Monday, versus Friday’s close of $3.03, extending a premarket decline into the regular session. Q2 results were the main catalyst: revenue of $1.636M missed the $2.100M consensus, even though the -$0.02 EPS loss was narrower than the -$0.03 estimate.

UMAC is trading down -11.63% at $30.10 during Monday's regular session, retreating from Friday's close of $34.06. The decline follows Friday's +25% surge to a 52-week high after President Trump announced tariffs of up to 100% on imported drones and components, favoring U.S.-based UMAC.

BALY is trading down -28.45% to $10.01 in Monday's regular session versus Friday's close of $13.99. The selloff follows Friday night's 10-Q filing, which disclosed "substantial doubt" about going-concern status and expected non-compliance with liquidity and leverage covenants.

SPCX gained +5.89% during regular trading, rising to $148.25 from Friday's $140.00 close. The advance extends a rebound that carried shares back above the $135 IPO price after the August 6 lockup expiry failed to trigger heavy selling.

NWBO is the ticker for Northwest Biotherapeutics, Inc., a clinical-stage biotechnology company focused on personalized cancer immunotherapy. The company's lead candidate, DCVax-L, targets glioblastoma, an aggressive form of brain cancer, and has completed a Phase III clinical trial.

SPXS fell approximately 11.6% over the trailing 30 days, moving from a closing price of $26.98 to a latest price near $23.86, as the S&P 500 advanced. Over the trailing three-month period, the fund declined roughly 13.9% , extending a downward trend driven by broad large-cap equity strength.

PURR is up +5.99% to $7.08 in regular trading versus the previous session close of $6.68. The gain is occurring during market hours after shares gapped higher in the premarket.